2 Matching Annotations
  1. Aug 2022
  2. www.medrxiv.org www.medrxiv.org
    https://medrxiv.org/cgi/content/10.1101/2021.11.24.21266831
    1
    1. jackiekrauss 29 Aug 2022

      Maier, B. F., Wiedermann, M., Burdinski, A., Klamser, P., Jenny, M. A., Betsch, C., & Brockmann, D. (2021). Germany’s current COVID-19 crisis is mainly driven by the unvaccinated (p. 2021.11.24.21266831). https://doi.org/10.1101/2021.11.24.21266831

      is:preprint lang:en COVID-19 Germany unvaccinated vaccine pharmaceutical tool 65% fully vaccinated symptomatic breakthrough infection vaccine uptake unvaccinated individual policy change pandemic response
    Visit annotations in context

    Tags

    Annotators

    URL

    medrxiv.org/content/10.1101/2021.11.24.21266831v1
  3. www.medrxiv.org www.medrxiv.org
    https://medrxiv.org/cgi/content/10.1101/2022.02.15.22270948
    1
    1. jackiekrauss 29 Aug 2022

      Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., Biber, A., Nemet, I., Kliker, L., Joseph, G., Doolman, R., Mendelson, E., Freedman, L. S., Harats, D., Kreiss, Y., & Lustig, Y. (2022). 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC (p. 2022.02.15.22270948). medRxiv. https://doi.org/10.1101/2022.02.15.22270948

      is:preprint lang:en COVID-19 Omicron immunogenicity efficacy safety mRNA vaccine fourth dose clinical intervention symptomatic disease healthcare worker breakthrough infection high viral load antibody titer next generation vaccine development
    Visit annotations in context

    Tags

    Annotators

    URL

    medrxiv.org/content/10.1101/2022.02.15.22270948v1.full.pdf